Copenhagen, 2016-01-11 07:56 CET (GLOBE NEWSWIRE) -- Exiqon A/S (Nasdaq Copenhagen: “EXQ”) today announced its expectations to full year 2015 results.
Exiqon expects total revenues around DKK 162 million and EBITDA around DKK 12 million in 2015 based on an average USD/DKK exchange rate of DKK 6.75.
Results are attributable to 25% growth in the company’s sale of proprietary products and services for RNA analysis.
Exiqon previously expected total revenues between DKK 155-160 million and EBITDA around DKK 10 million in 2015 based on an average USD/DKK exchange rate of DKK 6.50.
Exiqon announces the Annual Report 2015 on 8 February 2016.
Additional information
Lars Kongsbak, CEO, mobile phone: +45 4090 2101
Hans Henrik Chrois Christensen, CFO, mobile phone: +45 4090 2131
About Exiqon
At Exiqon, we advance the research of when and where genes are expressed. We empower scientists across the world with best-in-class products and user-friendly business solutions designed to transform workflows in our industry. Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for gene expression analysis. Academia, biotech and pharmaceutical companies around the world use Exiqon’s research products to make ground-breaking discoveries. Exiqon Diagnostics collaborates with diagnostic and pharmaceutical companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For more information about us, please visit www.exiqon.com
